Cargando…
Epstein-Barr virus as a marker of biological aggressiveness in breast cancer
PURPOSE: Although a potential role of the Epstein-Barr virus (EBV) in the pathogenesis of breast cancer (BC) has been underlined, results remain conflicting. Particularly, the impact of EBV infection on biological markers of BC has received little investigation. METHODS: In this study, we establishe...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031896/ https://www.ncbi.nlm.nih.gov/pubmed/21179039 http://dx.doi.org/10.1038/sj.bjc.6606048 |
_version_ | 1782197401951404032 |
---|---|
author | Mazouni, C Fina, F Romain, S Ouafik, L Bonnier, P Brandone, J-M Martin, P-M |
author_facet | Mazouni, C Fina, F Romain, S Ouafik, L Bonnier, P Brandone, J-M Martin, P-M |
author_sort | Mazouni, C |
collection | PubMed |
description | PURPOSE: Although a potential role of the Epstein-Barr virus (EBV) in the pathogenesis of breast cancer (BC) has been underlined, results remain conflicting. Particularly, the impact of EBV infection on biological markers of BC has received little investigation. METHODS: In this study, we established the frequency of EBV-infected BC using real-time quantitative PCR (RT–PCR) in 196 BC specimens. Biological and pathological characteristics according to EBV status were evaluated. RESULTS: EBV DNA was present in 65 of the 196 (33.2%) cases studied. EBV-positive BCs tended to be tumours with a more aggressive phenotype, more frequently oestrogen receptor negative (P=0.05) and with high histological grade (P=0.01). Overexpression of thymidine kinase activity was higher in EBV-infected BC (P=0.007). The presence of EBV was weakly associated with HER2 gene amplification (P=0.08). CONCLUSION: Our study provides evidence for EBV-associated BC undergoing distinct carcinogenic processes, with more aggressive features. |
format | Text |
id | pubmed-3031896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-30318962012-01-18 Epstein-Barr virus as a marker of biological aggressiveness in breast cancer Mazouni, C Fina, F Romain, S Ouafik, L Bonnier, P Brandone, J-M Martin, P-M Br J Cancer Molecular Diagnostics PURPOSE: Although a potential role of the Epstein-Barr virus (EBV) in the pathogenesis of breast cancer (BC) has been underlined, results remain conflicting. Particularly, the impact of EBV infection on biological markers of BC has received little investigation. METHODS: In this study, we established the frequency of EBV-infected BC using real-time quantitative PCR (RT–PCR) in 196 BC specimens. Biological and pathological characteristics according to EBV status were evaluated. RESULTS: EBV DNA was present in 65 of the 196 (33.2%) cases studied. EBV-positive BCs tended to be tumours with a more aggressive phenotype, more frequently oestrogen receptor negative (P=0.05) and with high histological grade (P=0.01). Overexpression of thymidine kinase activity was higher in EBV-infected BC (P=0.007). The presence of EBV was weakly associated with HER2 gene amplification (P=0.08). CONCLUSION: Our study provides evidence for EBV-associated BC undergoing distinct carcinogenic processes, with more aggressive features. Nature Publishing Group 2011-01-18 2010-12-21 /pmc/articles/PMC3031896/ /pubmed/21179039 http://dx.doi.org/10.1038/sj.bjc.6606048 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Mazouni, C Fina, F Romain, S Ouafik, L Bonnier, P Brandone, J-M Martin, P-M Epstein-Barr virus as a marker of biological aggressiveness in breast cancer |
title | Epstein-Barr virus as a marker of biological aggressiveness in breast cancer |
title_full | Epstein-Barr virus as a marker of biological aggressiveness in breast cancer |
title_fullStr | Epstein-Barr virus as a marker of biological aggressiveness in breast cancer |
title_full_unstemmed | Epstein-Barr virus as a marker of biological aggressiveness in breast cancer |
title_short | Epstein-Barr virus as a marker of biological aggressiveness in breast cancer |
title_sort | epstein-barr virus as a marker of biological aggressiveness in breast cancer |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031896/ https://www.ncbi.nlm.nih.gov/pubmed/21179039 http://dx.doi.org/10.1038/sj.bjc.6606048 |
work_keys_str_mv | AT mazounic epsteinbarrvirusasamarkerofbiologicalaggressivenessinbreastcancer AT finaf epsteinbarrvirusasamarkerofbiologicalaggressivenessinbreastcancer AT romains epsteinbarrvirusasamarkerofbiologicalaggressivenessinbreastcancer AT ouafikl epsteinbarrvirusasamarkerofbiologicalaggressivenessinbreastcancer AT bonnierp epsteinbarrvirusasamarkerofbiologicalaggressivenessinbreastcancer AT brandonejm epsteinbarrvirusasamarkerofbiologicalaggressivenessinbreastcancer AT martinpm epsteinbarrvirusasamarkerofbiologicalaggressivenessinbreastcancer |